April 9, 2015—The coming “tsunami” of high-priced specialty drugs for cancer and other chronic conditions threatens to undermine the U.S. healthcare system’s financial integrity, a panel representing physicians, patients, and payers warned at a Capitol Hill briefing today organized by the Campaign for Sustainable Rx Pricing.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)